Thermo Fisher Scientific Inc
- Branche
- Life Science Tools
- Börse
- USA
- Land / Region
- USA
- Börsengang
- 13. Januar 1978
- Mitarbeiter
- 125.000
- Website
- www.thermofisher.com
Zusammengesetzter Bewertungsbereich · konservativ $340–$385 / fair $440–$495 / optimistisch $545–$615. Bei $559.53, Innerhalb des optimistischen Bereichs des inneren Werts · viele Erwartungen eingepreist.
Bei Veröffentlichung $448.28 (25. Mai 2026)
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Geschichte
Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts, with an IPO date of January 13, 1978. Under its "serving science" mission, the company grew through long-term acquisition integration led by CEO Marc Casper, who has held the role since 2009. It now operates through four segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services—and employs about 125,000 people across a portfolio of brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon, and PPD.
Branchenposition
Thermo Fisher provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services to pharmaceutical and biotech firms, academic and government research institutions, hospitals, clinical labs, and industrial and environmental customers in North America, Europe, Asia-Pacific, and internationally. In 2025 it generated revenue of USD 44.556 billion. Its competitors include Danaher (2025 sales about USD 24.568 billion), Agilent (fiscal 2025 net revenue about USD 6.948 billion), and Waters (2025 net sales about USD 3.165 billion).
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.